DNMT1 and autosomal dominant polycystic kidney disease: It was theorised by Woo et al. [75] that if the hypermethylation of the ADPKD genome was resulting in cystogenesis, pharmaceuticals, such as the DNMT inhibitor decitabine, could be used for the treatment and management of ADPKD patients.